Arkolith/Insider Trading/ITCI/Form 4

Neumann Mark

EVP, Chief Commercial OfficerIntra-Cellular Therapies, Inc. (ITCI) · full profile →Form 4 · filed Mar 10, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 10, 2025Tax withholding(F)3K$131.24$409K53K
Mar 10, 2025Option exercise(M)7K——56K
Mar 6, 2025Tax withholding(F)6K$131.19$731K49K
Mar 6, 2025Option exercise(M)13K——54K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 10, 2025Option exercise(M)7K—$00
Mar 6, 2025Option exercise(M)13K—$013K

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-036592) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML